Few, if any, industries have investors more excited right now than cannabis. Depending on your preferred source, the global weed industry could see sales grow from $12.2 billion in 2018 to perhaps $50 billion to $75 billion annually in roughly a decade’s time.
But at the heart of that growth is the United States. In Bank of America analyst Christopher Carey’s utopian model, whereby the marijuana industry reaches $166 billion in yearly sales, the United States is responsible for generating 34% of this annual revenue. The U.S. is, for all intents and purposes, the crown jewel of the cannabis movement, which is what makes U.S. pot stocks such a potentially hot commodity.
There are a number of popular vertically integrated dispensary operators in the United States that you’re probably familiar with, including the relatively upscale MedMen Enterprises, which is attempting to normalize the cannabis-buying experience, or Curaleaf Holdings, which snagged a deal a few months back to get its topical cannabidiol (CBD)-infused products into CVS Health stores. You might also be familiar with Acreage Holdings, the multistate dispensary operator that agreed to be acquired for $3.4 billion by the largest pot stock in the world by market cap, Canopy Growth,